Ilona Csizmadi
Overview
Explore the profile of Ilona Csizmadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho V, Csizmadi I, Boucher B, McInerney M, Boileau C, Noisel N, et al.
BMJ Open
. 2024 Aug;
14(8):e083425.
PMID: 39153764
Purpose: To address emerging nutritional epidemiological research questions, data from contemporary cohorts are needed. CARTaGENE is the largest ongoing prospective cohort study of men and women in Québec, Canada. Dietary...
2.
3.
Liu I, Gu L, De Hoedt A, Cooperberg M, Amling C, Kane C, et al.
Cancer Causes Control
. 2023 Jul;
34(11):983-993.
PMID: 37405681
Purpose: Obesity and smoking have been associated with poor prostate cancer (PC) outcomes. We investigated associations between obesity and biochemical recurrence (BCR), metastasis, castrate resistant-PC (CRPC), PC-specific mortality (PCSM), and...
4.
Sergeyev A, Gu L, De Hoedt A, Amling C, Aronson W, Cooperberg M, et al.
Cancer Epidemiol Biomarkers Prev
. 2023 Jun;
32(9):1208-1216.
PMID: 37294698
Background: The prognosis of diabetic men with advanced prostate cancer is poorly understood and understudied. Hence, we studied associations between diabetes and progression to metastases, prostate cancer-specific mortality (PCSM) and...
5.
Pereira V, Oyekunle T, Janes J, Amling C, Aronson W, Cooperberg M, et al.
Prostate
. 2023 Apr;
83(11):1011-1019.
PMID: 37096737
Background: We previously showed that within an equal-access health system, race was not associated with the time between prostate cancer (PC) diagnosis and radical prostatectomy (RP). However, in the more...
6.
Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial
Kramer J, Gu L, Moreira D, Andriole G, Freedland S, Csizmadi I
Prostate
. 2023 Apr;
83(10):990-997.
PMID: 37070723
Background: Benign prostatic hyperplasia is common in older men, with many developing lower urinary tract symptoms (LUTS) that impair quality of life. Smoking has many well-established adverse effects, but its...
7.
Friedrich N, Freedland S, Csizmadi I
Prostate Cancer Prostatic Dis
. 2022 Oct;
26(3):445-446.
PMID: 36261588
No abstract available.
8.
Anderson E, Gu L, Oyekunle T, De Hoedt A, Wiggins E, Gay C, et al.
Prostate Cancer Prostatic Dis
. 2022 May;
25(3):593-595.
PMID: 35618798
Sociodemographic and lifestyle factors may play a role in determining whether patients with clinically localized prostate cancer (PC) are managed with active surveillance (AS), radical prostatectomy (RP), or radiation therapy...
9.
Barlow S, Oyekunle T, Janes J, De Hoedt A, Aronson W, Kane C, et al.
Prostate
. 2021 Dec;
82(3):366-372.
PMID: 34905632
Background: Smaller prostates have been linked to unfavorable clinical characteristics and poor short-term outcomes following radical prostatectomy (RP). We examined the relation between prostate weight at RP and prostate cancer...
10.
Kramer J, Gu L, Moreira D, Andriole G, Csizmadi I, Freedland S
J Urol
. 2021 Sep;
207(2):417-423.
PMID: 34544265
Purpose: Benign prostatic hyperplasia (BPH) is a common disease often manifested by lower urinary tract symptoms (LUTS). We previously found statins were associated with modest attenuations in prostate growth over...